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The activities of protease inhibitors in vivo may depend on plasma concentrations and viral susceptibility.
This nonrandomized, open-label study evaluated the relationship of the inhibitory quotient (IQ [the ratio of
drug exposure to viral phenotypic susceptibility]) to the human immunodeficiency virus type 1 (HIV-1) viral
load (VL) change for ritonavir-enhanced protease inhibitors (PIs). Subjects on PI-based regimens replaced
their PIs with ritonavir-enhanced indinavir (IDV/r) 800/200 mg, fosamprenavir (FPV/r) 700/100 mg, or
lopinavir (LPV/r) 400/200 mg twice daily. Pharmacokinetics were assessed at day 14; follow-up lasted 24 weeks.
Associations between IQ and VL changes were examined. Fifty-three subjects enrolled, 12 on IDV/r, 33 on
FPV/r, and 8 on LPV/r. Median changes (n-fold) (FC) of 50% inhibitory concentrations (IC50s) to the study PI
were high. Median 2-week VL changes were 0.7, 0.1, and 1.0 log10 for IDV/r, FPV/r, and LPV/r. With
FPV/r, correlations between the IQ and the 2-week change in VL were significant (Spearman’s r range, 0.39
to 0.50; P < 0.029). The strongest correlation with response to FPV/r was the IC50 FC (r  0.57; P  0.001),
which improved when only adherent subjects were included (r  0.68; P  0.001). In multivariable analyses of
the FPV/r arm that included FC, one measure of the drug concentration, corresponding IQ, baseline VL, and
CD4, the FC to FPV was the only significant predictor of VL decline (P < 0.001). In exploratory analyses of all
arms, the area under the concentration-time curve IQ was correlated with the week 2 VL change (r  0.72;
P < 0.001). In conclusion, in PI-experienced subjects with highly resistant HIV-1, short-term VL responses to
RTV-enhanced FPV/r correlated best with baseline susceptibility. The IQ improved correlation in analyses of
all arms where a greater range of virologic responses was observed.
Ritonavir (RTV)-enhanced protease inhibitors (PIs) are a
cornerstone of therapy for human immunodeficiency virus
(HIV)-infected treatment-experienced patients with resistant
virus (8, 11, 12, 17, 19). The antiretroviral response to RTV-
enhanced PIs is related to the susceptibility of the individual’s
virus to the specific agent. Multiple studies of PIs have dem-
onstrated a relationship between the drug concentration and
the virologic response (reviewed in reference 5), although
whether there is an upper threshold of virus resistance that
cannot be overcome with increased PI concentration is not
known.
Measured drug exposure may enhance the predictive value
of virus susceptibility as assessed, for example, by the 50%
inhibitory concentration (IC50). A ratio of drug exposure to
virus susceptibility, termed the inhibitory quotient (IQ) ratio,
may predict the short- and long-term virologic responses to
PI-based therapy better than susceptibility alone. Conflicting
results have been reported, with some studies demonstrating
no added benefit to incorporating pharmacokinetics informa-
tion (reviewed in references 13 and 16). In studies of lopinavir-
RTV (LPV/r), an independent relationship between IQ and
outcome has been seen in some studies (20), but not others (4,
14, 15). Published studies of amprenavir (APV) or fosam-
prenavir (FPV [APV’s prodrug]) IQs have been small (10).
One study showed an independent relationship between an
APV genotype-based IQ and virologic response (21), two
showed that the IQ did not add significantly to baseline geno-
typic resistance (7, 26), and a third showed a correlation with
the 2-week viral load (VL) response that was lost when a single
outlier was removed from the analysis (4).
Additional rigorous prospective evidence is needed to test
whether the IQ adds additional predictive information to base-
line resistance testing of antiretroviral response in patients
with substantial PI resistance. Such data would support the use
of PI concentrations for monitoring antiretroviral therapy. We
hypothesized that the ratio of the PI concentration over the
susceptibility of an individual’s virus to that PI could predict
antiretroviral response more robustly than HIV type 1 (HIV-1)
drug susceptibility alone in a short-term, focused clinical trial.
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In this study, our objective was to evaluate the correlation
between the IQ ratios (concentration at 12 h [C12]/IC50) for
each PI and the short- and long-term antiretroviral activities of
three RTV-enhanced PIs in individuals who had failed previ-
ous PI-based regimens.
(The results of this study were presented in part in abstract/
poster L-123 at the 13th Conference on Retroviruses and Op-
portunistic Infections, Denver, CO, 5 to 8 February 2006
[ClinicalTrials.gov identifier NCT00027339].)
MATERIALS AND METHODS
Study design, subject selection, and dosing. This was a phase II, nonrandom-
ized, open-label, parallel-arm study conducted at 16 sites in the United States.
Antiretroviral-experienced, HIV-infected subjects were eligible if they were 18
years of age, had plasma HIV-1 RNA levels of 2,500 copies/ml, had received a
PI-based regimen for 12 weeks immediately before the study, had 48 weeks
of PI-based treatment experience, had safety laboratory values within prespeci-
fied ranges, and had phenotypic confirmation within the prior 60 days of de-
creased susceptibility (2.5-fold) to at least two of three PIs to be used in the
study. Exclusion criteria included recent receipt of HIV vaccines, investigational
drugs, immunotherapies, hydroxyurea, or significant renal disease. The study was
approved by the Institutional Review Board at each study site. All subjects gave
written informed consent.
At study entry, the subjects discontinued their PIs, continued all other back-
ground antiretrovirals, and began a 14-day period on one of the following
treatments: arm A, indinavir 800 mg plus RTV 200 mg (IDV/r) twice daily
(BID); arm B, FPV 700 mg plus RTV 100 mg (FPV/r) BID; or arm C, LPV/r 400
mg/100 mg BID plus additional RTV 100 mg BID (LPV/r/r). Subjects who
received IDV/r or LPV/r immediately before entry were ineligible for arm A or
arm C, respectively, whereas subjects on APV/RTV or FPV/r prestudy were
ineligible for arm B. On day 15, tenofovir disoproxil fumarate was added, and
background therapy could be optimized. Enfuvirtide (Fuzeon) and/or a non-
nucleoside reverse transcriptase inhibitor was allowed. Treatment continued for
24 weeks. IDV 800 mg was supplied as two 400-mg Crixivan capsules (Merck &
Co., Inc., Whitehouse Station, NJ), LPV/r 400 mg/100 mg as Kaletra capsules
(Abbott Laboratories, North Chicago, IL) containing LPV/r 133.3 mg/33.3 mg,
FPV 700 mg as Lexiva 700-mg tablets (GlaxoSmithKline, Research Triangle
Park, NC), and RTV as 100-mg Norvir capsules (Abbott Laboratories, North
Chicago, IL). The planned sample size was 36 subjects per arm to detect a
minimum correlation of 0.5 between the IQ and the VL response with 80%
power at a 0.05 level of significance.
Pharmacokinetics analysis. On day 14, blood samples were collected just
before the morning dose (zero hour) and at 1, 2, 3, 6, 9, and 12 h postdose. The
samples were analyzed using validated liquid chromatography-tandem mass
spectrometry with lower limits of quantification for IDV, APV, LPV, and RTV
of 10, 44, 40, and 25 ng/ml, respectively. The pharmacokinetics parameters,
assessed for each PI by standard noncompartmental methods included the area
under the concentration-time curve from 0 to 12 h postdose (AUC0-12), C12, the
maximum plasma concentration (Cmax), the minimum plasma concentration
(Cmin), time to Cmax (Tmax), and the trough concentration obtained immediately
prior to the morning dose (C). C was also determined at study weeks 4, 8, and
24, prior to an observed dose. AUC0-12 was calculated by the linear trapezoidal
method. Protein binding (PB) was assessed by equilibrium dialysis for APV and
LPV on samples taken twice on day 14, at the estimated peak concentration (2
h postdose for APV and 6 h postdose for LPV), at 12 h, and at week 24 using
validated assays with interday and intraday variation of 12%. The percentage
of free drug was then calculated. The individual free-drug-adjusted C12 and
AUC0-12 were determined based on the average of the two free-drug percentages
multiplied by the total C12 and AUC0-12 values obtained at week 2.
Pharmacodynamic analysis. Before entry, the subjects had an antiretroviral
phenotype obtained using the PhenoSense assay (Monogram Biosciences). The
resistance parameters included the measured IC50 and the IC50 change (n-fold)
(FC). For each subject, six IQs were calculated based on their pharmacokinetics
and resistance results. Four sets were based on the absolute IC50 either without
a correction for PB (IQnIC) or with different correction factors, including mul-
tiplication of the IC50 by the attenuation by 50% human serum (IQcIC) (17a),
multiplication of the pharmacokinetics parameter by population PB (IQpIC) (2,
15a, 18, 24), and, for LPV and APV, multiplication by the actual measured
individual free-drug percentage for the individual subject (IQfIC). Two sets were
based on FC, in which a wild-type IC50 (the mean IC50 of three standard variants
measured in 50% human serum [22]) was multiplied by the FC from the Phe-
noSense assay. One FC IQ used the total measured drug (IQFC); the other, for
LPV and APV, multiplied the pharmacokinetics parameter by the measured
individual free-drug percentage (IQfFC). These IQs were calculated using one of
several pharmacokinetics parameters, including C12, AUC0-12, and C.
Efficacy analysis. VLs were obtained at screening (day 60), preentry (day
14), entry (day 0), days 7 and 14 (two values), and weeks 4, 8, 16, and 24 (Roche
UltraSensitive assay; lower limit of quantification, 50 copies/ml). The baseline
VL was the geometric mean of the screening, preentry, and entry values. CD4
and CD8 cell counts were obtained at preentry, entry, and weeks 2, 8, and 24.
Safety analysis. Adverse events, including signs, symptoms, and laboratory
abnormalities, were graded using the standardized Division of AIDS, National
Institute of Allergy and Infectious Disease, toxicity grading criteria. Safety anal-
yses focused on grade 3 (severe) and higher adverse events.
Adherence analysis. Adherence was measured using the electronic medication
event monitoring system (MEMS Cap) attached to RTV bottles.
Statistical methods. (i) Pharmacokinetics data analysis. Differences in PI C
levels within arms were compared using the Kruskal-Wallis test. A paired com-
parison of C levels between weeks 2 and 24 for arm B (FPV) was also performed
using the Wilcoxon signed-rank test. For FPV and LPV, differences in per-
centages of free APV and LPV between pairs of scheduled times were
evaluated using the Wilcoxon signed-rank test. PI AUC0-12, C12, Cmax, and C
were compared for subjects in each treatment arm who experienced toxicities
of grade 3 with values for subjects with toxicities of grade 3 using the
Wilcoxon rank-sum test.
(ii) Pharmacodynamic-efficacy relationship data analysis. For each PI, the
resistance markers among the treatment arms were compared by the Kruskal-
Wallis test. Correlation of short-term (day 14) and long-term (week 24) VL
changes from baseline with IQ ratios, IC50, FC, AUC0-12, C12, Cmax, and C were
tested for significance using Spearman’s rank correlation test and simple linear
regression. Differences in CD4 and CD8 cell count changes between weeks 2 and
24 were evaluated by the Wilcoxon signed-rank test.
(iii) Efficacy-adherence relationship data analysis. The significance of corre-
lations between VL changes and adherence was evaluated using Spearman’s rank
correlation test and linear regression analysis. All statistical tests were two-tailed
using a 0.05 level of significance.
RESULTS
Baseline characteristics, resistance, and treatment disposi-
tion. Fifty-three subjects enrolled in the study: 12 on IDV/r, 33
on FPV/r, and 8 on LPV/r/r. The subjects were racially and
ethnically diverse: 30% were white, 36% black, and 30% His-
panic. Eleven percent (6/53) were women. In the IDV/r,
FPV/r, and LPV/r/r arms, the median baseline plasma HIV-1
RNAs were 5.0, 4.6, and 4.3 log10 copies/ml; the CD4 counts
were 43, 142, and 287 cells/mm3; the times from initiation of
first antiretroviral therapy to study entry were 6.6, 8.4, and 7.1
years; the numbers of previous PIs were 4, 5, and 3; and the
median total years of prior PI treatment were 6.6, 7.2, and 5.3,
respectively.
The subjects generally had highly PI-resistant virus. The
baseline median FCs for LPV were 157 in the IDV/r arm, 79 in
the FPV/r arm, and 20.5 in the LPV/r arm; for IDV, they were
33, 42, and 16 in these arms, respectively; and for FPV, they
were 72.5, 12, and 37, respectively. The treatment arm was
chosen by local investigators based on preentry resistance test-
ing, and FCs differed significantly among the treatment arms
(P  0.02). In each arm, more than 50% of the subjects had
FCs of 10 to the chosen agent.
Forty seven (89%) subjects completed the protocol on their
assigned PI (94% [31/33] in the FPV/r arm). Three subjects
(one in each arm) did not complete the 24-week protocol.
Optimized regimens included a median of 2.5 nonnucleoside
reverse transcriptase inhibitors. Only five subjects, all in the
FPV/r arm, initiated enfuvirtide as a new agent.
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Pharmacokinetics. Forty-nine subjects had 12-hour pharma-
cokinetics assessments at day 14, with results from two subjects
each missing in the IDV/r and FPV/r arms. The data for the
FPV/r arm are in Table 1. Median APV C values for the
FPV/r arm were stable over time and similar to the day 14
median C12 value. Within-subject APV C values were also
stable over time (data not shown). The median C12 (ng/ml) for
IDV (n  10) was 806.0 (interquartile range [IQR], 469.00,
1,140.00), and for LPV (n  8), the median was 6,880.0 (IQR,
5,914.00, 9,235.00).
For the FPV/r and LPV/r arms, the percentages of drug free
of PB are shown in Table 2, along with the protein-adjusted
AUC0-12s for FPV and LPV. The percentages free for each
drug were similar across time points. For FPV, the percentage
of free drug at peak was slightly but significantly higher than at
12 h (P  0.011; Wilcoxon signed-rank test). Values from
individual subjects at Cmax and C were correlated (r  0.61;
P  0.001). The percentage free at the week 24 C was not
significantly different than at 12 h on day 14, and the values
were highly correlated (r  0.86; P  0.001), with the estimated
linear regression line virtually overlapping a 45° straight line
representing one-to-one correlation (data not shown).
IQ. IQ values using day 14 C12 concentrations (Table 3)
were highest when PB was ignored and varied between treat-
ment arms when different methods were used to correct for
PB. The values were most consistent between arms when es-
timates for free-drug percentages from population studies
were used (C12_IQpIC), and these IQs were similar to values
obtained when measured individual-subject free-drug concen-
trations were used (C12_IQfIC) for the FPV/r and LPV/r arms.
Treatment response. Median changes in plasma HIV-1
RNA levels from baseline were modest. At 2 weeks, the FPV/r
arm had a median change in plasma HIV RNA of 0.1 log10
copies/ml (range, 1.1 to 0.9 log10 copies/ml). For the IDV/r
arm, the median change in plasma HIV RNA was 0.7 (range,
1.6 to 0.6), and for the LPV/r/r arm, it was 1.0 (range,
1.7 to 0.1). Of the 32 subjects treated with FPV/r, 21 had
switched from LPV/r and 6 had previous APV exposure. Week
24 results varied widely among individuals. Median changes
within arms were small. In the FPV/r arm, the median change
for plasma HIV RNA was 0.3 (range, 3.2 to 1.0). In the
IDV/r arm, it was 0.4 (range, 2.9 to 0.3), and in the
LPV/r/r arm, it was 0.3 (range, 2.9 to 0.2).
Correlations for week 2 treatment response in the FPV/r
arm. Given that the sample size in the FPV/r arm approached
the prespecified target, our analyses focused on this arm. The
correlation between the FPV C12 IQ and 2-week VL response
was modest and significant with or without correction for PB
and when measured free-drug concentrations were used (Ta-
ble 3). However, the strongest correlation with the 2-week
treatment response to FPV/r substitution was the baseline IC50
FC (Fig. 1a) (Spearman r  0.57; P  0.001), which improved
further when the analysis was limited to adherent subjects who
took 80% of the RTV doses in the first 14 days (Spearman
r  0.68; P  0.001) (Fig. 1b). Accounting for FPV exposure
using IQ ratios did not improve on these correlations (Table
3). All correlations between the IQ (using C12, C, or AUC0-12
and various measures of susceptibility) and the 2-week re-
sponse, though significant, had less significant R values, with
the exception of the IQ using AUC and FC susceptibility
(AUC_IQFC), which had the same correlation (r  0.57; P 
0.001) (Fig. 2a) and was more robust than the correlation
observed with C12_IQFC (r  0.44; P  0.014) (Fig. 2b).
Incorporating individual measured percentages free for APV
improved the IQ correlation using FC for the C12_IQfFC (r 
0.5; P  0.005), though not for the AUC_IQfFC (r  0.51;
P  0.004). Accounting for adherence modestly improved the
observed correlation for most comparisons. No single pharma-
cokinetics parameter (Cmax, AUC0-12, C12, or average C)
showed an inverse relationship between an increasing concen-
tration and a greater decrease in change in VL at 2 weeks. All
correlation coefficients were positive and nonsignificant (Cmax,
r  0.27; AUC0-12, r  0.26; C12, r  0.20; and C, r  0.18).
The relationships of baseline susceptibility or IQ with
change in VL from baseline at 24 weeks in the FPV/r arm had
correlations similar to those of the short-term results; most
were not significant. Examining the VL change at day 7 in the
FPV/r arm did not change the relationships. The correlation
coefficients and P values for the relationships between week 2
VL responses and IQ ratios are listed in Table 3 for LPV/r and
IDV/r. None were significant, nor were correlations between
FC and response (data not shown). Inverse relationships be-
TABLE 1. Pharmacokinetics parameters at day 14 and trough
concentrations over time for the FPV/r arma
Parameter n Median IQR
AUC(0-12) (ng · h/ml) 31 35,370 26,622, 51,740
C12 (ng/ml) 2,060.00 1,300.00, 2,850.00
Cmax (ng/ml) 4,970.00 3,960.00, 7710.00
Tmax (h) 3.00 2.00, 6.00
C (ng/ml)
Week 2 25 2,450 1,910, 3,100
Week 4 21 2,330 1,780, 3,480
Week 8 21 2,480 1,890, 3,740
Week 24 20 2,020 1,475, 2,855
a The longitudinal data for IDV and LPV are not shown due to the limited
sample sizes for these arms. Pharmacokinetics data following FPV/r dosing refer
to APV.
TABLE 2. Percentages of drug free of PB and PB-adjusted AUCa
Arm Sampling time





FPV/r Week 2, h 2 28 8.36 4.77, 13.01
Week 2, h 12 31 7.53 5.10, 11.58
Week 24, trough 23 6.60 3.93, 13.25
Overall 82 7.87 3.93, 13.25
LPV/r Week 2, h 6 8 1.03 0.64, 1.51
Week 2, h 12 8 0.94 0.56, 1.15
Week 24, trough 5 1.03 0.46, 1.18
Overall 21 1.01 0.46, 1.51
a The PB-adjusted AUC0-12 values (ng · h/ml) for the FPV/r (n  30) and
LPV/r (n  8) arms median (range), respectively, were as follows: 287.7 (153.4,
717.4) and 110.4 (67.2, 151.2).
b The longitudinal data for IDV are not shown, as % free drug was not
measured for IDV arms. Pharmacokinetics data following FPV/r dosing refer to
APV.
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tween measures of concentration and treatment response were
also not observed.
Using FPV/r data, multivariate regression analyses by step-
wise selection investigated the relationships of VL changes at
week 2 with potential predictors of response. The variables
included baseline VL and CD4 and CD8 cell counts; one
measure of susceptibility (IC50, FC, or mean wild-type IC50 	
FC); one measure of the week 2 drug concentration; and the
corresponding IQ ratio. Baseline susceptibility to FPV was the
only significant predictor of VL decline in all models that
included the FC variable (P  0.001). In one model that in-
cluded the IQ based on individual measured free-APV AUC
and the actual IC50, the AUC_IQfIC was the only significant
predictor (P  0.001).
When data from all three arms were combined in an explor-
atory analysis, the IQ based on C12 and FC susceptibility
(C12_IQFC) was correlated with the week 2 change in VL (r 
0.53; P  0.001), and when the LPV/r and FPV/r arms were
combined, the IQ based on the measured free C12 value and
FC (C12_IQfFC) was also significantly correlated with the week
2 and week 24 VL responses (r  0.47 for both; P  0.003
and 0.004). The combined-arm analysis using the IQ based on
the AUC and FC (AUC_IQFC) gave the strongest correlation
(r  0.72; P  0.001) of any comparison. Unlike the analysis
for the FPV/r arm, the combined analysis showed only modest
correlation between either the IC50 or the FC and the week 2
VL response (r  0.41, P  0.003 and r  0.25, P  0.078,
respectively).
Tolerability/toxicity results. Few subjects had grade 3 or
greater signs, symptoms, or laboratory abnormalities through
24 weeks (4/12 on IDV/r, 9/33 on FPV/r, and none on LPV/r).
Approximately one-half were considered possibly or definitely
study drug related. None were unanticipated. No significant
relationships between drug concentrations and toxicity were
found.
DISCUSSION
This study was designed to rigorously assess the relation-
ships of pharmacokinetics parameters (including measured
free-drug concentrations for the more highly protein-bound
PIs), PI susceptibility, and IQ with short- and long-term treat-
ment responses. Only the PI component of the regimen was
changed over the first 14 days to limit confounding, and ad-
herence over this period was measured by MEMS Caps. The
FPV/r arm accrued enough subjects to reliably evaluate treat-
ment response. Most subjects had highly PI-resistant virus,
resulting in limited treatment responses. In the FPV/r arm,
most subjects had FC IC50s of 10, designated to be above the
upper treatment response cutoff in the PhenoSense assay.
Somewhat greater 2-week treatment responses were observed
in the IDV/r and LPV/r arms, despite higher median FCs at
baseline; however, the nonrandomized nature of the study
precludes comparisons among arms. Despite the limitations,
several important observations can be made.
The pharmacokinetics results for IDV/r, FPV/r, and LPV/r
are consistent with previous reports (1, 9). APV AUC values
were similar to those noted in a recent large pharmacokinetics
study, although we observed higher APV C12 and C values
(23). APV concentrations 12 h postdose were similar to pre-
dose C and median C in FPV/r-treated subjects. Within-
subject APV C values were consistent over time. The percent-
ages of free APV and LPV were consistent with previous
reports (3, 6), and these values remained stable over time. In
the FPV/r arm, we demonstrated that at Cmax, the proportion












a IDV/r 10 9.091 (1.870, 61.495) 0.02 0.96
FPV/r 31 19.556 (1.802, 105.570) 0.39 0.029
LPV/r 8 156.735 (16.969, 831.806) 0.38 0.36
C12_IQFC
b IDV/r 10 0.756 (0.168, 7.378) 0.09 0.80
FPV/r 31 0.541 (0.039, 2.484) 0.44 0.014
LPV/r 8 5.320 (0.740, 32.415) 0.24 0.58
C12_IQcIC
c IDV/r 10 4.329 (0.890, 29.284) 0.02 0.96
FPV/r 31 5.146 (0.474, 27.782) 0.39 0.029
LPV/r 8 40.189 (4.351, 213.283) 0.38 0.36
C12_IQpIC
d IDV/r 10 3.636 (0.748, 24.598) 0.02 0.96
FPV/r 31 1.956 (0.180, 10.557) 0.39 0.029
LPV/r 8 2.351 (0.255, 12.477) 0.38 0.36
C12_IQfIC
e FPV/r 30 1.494 (0.145, 7.949) 0.47 0.01
LPV/r 8 1.179 (0.095, 7.960) 0.38 0.36
C12_IQfFC
f FPV/r 30 0.039 (0.003, 0.187) 0.50 0.005
LPV/r 8 0.056 (0.005, 0.310) 0.26 0.54
a C12_IQnIC  C12/IC50.
b C12_IQFC  C12/mean wild-type IC50 (22) 	 IC50 FC.
c C12_IQcIC  C12/IC50 	 attenuation by 50% human serum (18).
d C12_IQpIC  population PB-corrected C12 (2, 14, 18, 24)/IC50.
e C12_IQfIC  individual PB-corrected C12/IC50.
f C12_IQfFC  individual PB-corrected C12/mean wild-type IC50 (22) 	 IC50 FC.
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postdose and that the percentages of free APV within individ-
uals on the FPV/r arm were highly correlated and stable over
time. APV percentages free were less variable than previously
reported in a smaller study of APV/r (3).
We demonstrated that IQs vary widely for a given PI and
across different PIs depending upon whether and how one
controls for PB. For APV and LPV, the PB correction method
using average free-drug percentages obtained from previous
studies (2, 15a, 18, 24) resulted in IQ ratios that were numer-
ically closest to the ratio created using measured free-drug
percentages from the individual subjects.
In the evaluation of predictors of treatment response in the
FPV/r arm, short-term (2-week) antiretroviral treatment re-
sponses to FPV/r correlated most strongly with baseline FC
susceptibility to FPV (Fig. 1a). Accounting for adherence im-
proved the relationship further (Fig. 1b). The correlation with
the treatment response was not improved by incorporating
drug exposure information. Multiple different IQ formulas
were evaluated, and only the IQ that incorporated AUC0-12
and FC susceptibility had a correlation coefficient that was the
same as the FC susceptibility (Fig. 2a). Similarly, in multivar-
iate regression models that included baseline susceptibility
(measured as FC), drug exposure, IQ, baseline HIV RNA, and
baseline CD4, only baseline FC significantly predicted the out-
come. Although PI concentration ranges for patients on
boosted PI are broad, higher plasma APV concentrations did
not appear to contribute to inhibition of highly PI-resistant
virus, which was present in most of our FPV/r-treated subjects,
suggesting that increasing PI plasma concentrations cannot
overcome very high-level PI resistance for a given PI, even
when the amount of free drug present is accounted for. We
FIG. 1. (a) Plot of log RNA change versus IC50 FC (on a loge scale)
and estimated log RNA change as a function of IC50 FC (linear
regression model). (b) Plot of log RNA change versus IC50 FC (on a
loge scale) and estimated log RNA change as a function of IC50 FC for
subjects with at least 80% adherence (AH) (linear regression model).
FIG. 2. (a) Plot of log RNA change versus the reciprocal of AUC_
IQFC (on a loge scale) and estimated log RNA change as a function of the
reciprocal of AUC_IQFC (linear regression model). AUC_IQFC  AUC/
[mean wild-type IC50 of reference strains 	 IC50 FC]. (b) Plot of log RNA
change versus the reciprocal of C12_IQFC (on a loge scale) and estimated
log RNA change as a function of the reciprocal of C12 _IQFC (linear
regression model).
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used the approved dose of FPV/r (700/100 mg BID), and
perhaps a higher dose could improve the inhibition of highly
resistant virus, although the drug levels others have achieved at
1,400/100 mg BID were not dose-proportionally increased
(25). In exploratory analyses using all three arms, where the
range of week 2 VL responses was greater, accounting for
concentration and susceptibility (IQ) produced stronger cor-
relations than with susceptibility alone. The IQ using AUC and
FC resulted in the strongest correlation we observed. These
results suggest that when there is a broader range of variant
susceptibility and treatment responses, incorporating the drug
concentration and susceptibility improves the correlation with
virologic response over susceptibility alone.
Our findings, when evaluating the FPV/r arm, are consistent
with some but vary from other previous observations from
studies that were not prospectively designed to evaluate IQ. In
an early study of LPV/r when efavirenz was also administered
as a new agent, the LPV IQ was a significant predictor of
antiretroviral treatment response in multivariate regression
models. These models did not include baseline susceptibility as
a separate variable (15). In a large study evaluating a genotype
IQ for LPV (GIQ), both the genotype and GIQ were predic-
tive of the 6-month outcome in multivariable models, and in
contrast to our results with FPV/r and phenotype-based IQ, in
subjects with high-level LPV resistance, the GIQ was the only
significant predictor of the outcome (20). In two studies of
phenotype-based and genotype-based APV IQs, a higher IQ
was associated with an improved outcome, but statistical anal-
yses were limited (10, 21). In one study of APV/r in subjects
with high levels of resistance at baseline, the genotype and not
the GIQ was predictive of the response (26), consistent with
our results, although in another, larger study of FPV/r in treat-
ment-experienced subjects with a broad range of genotypic
resistance to FPV, a significant independent relationship be-
tween GIQ and 12-week treatment outcome was demonstrated
(23). Consistent with our exploratory analysis, the relationship
between IQ and treatment response is most apparent when
there is a broad range of susceptibility in the population stud-
ied, which would be more likely for PIs with activity across a
large FC range.
Our study was limited, as only the FPV/r arm accrued suf-
ficient subjects to make robust comparisons within an arm, and
the levels of baseline APV resistance blunted the range of
treatment responses. Conversely, our study was unique in that
it was prospectively designed to address the correlation of IQ
with outcome, included a full pharmacokinetics analysis with
measurement of free-drug percentages, and measured adher-
ence. The 2-week treatment response reflected the single sub-
stitution and was not confounded by changes to other regimen
components. Overall, we could not demonstrate an improve-
ment in the correlation of treatment response with IQ com-
pared to baseline virus susceptibility to FPV, though an ex-
ploratory analysis across the three arms was suggestive.
Whether the IQ may provide a better predictor of outcome in
individuals with more sensitive virus requires further study.
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